Saviynt's cloud-native IGA and AAG solution — providing fine-grained access entitlements and cross-application separation of duties (SoD) controls to meet changing SOX compliance requirements.
A world leader in developing and commercializing innovative therapies for rare diseases, this biotech company is a mission-driven organization that takes pride in creating pioneering treatments that save lives and better the current standard of care. Challenged to meet compliance requirements and rapid growth, the company needed to modernize its identity and access governance strategy.
With Saviynt’s solution, the company has automated access provisioning for a full suite of business-critical applications and more than 5,000 global employees – all while reducing third-party technical support and administrative labor costs by approximately 50%.